Companies Pacira BioSciences, Inc.
Pacira BioSciences (PCRX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Pacira BioSciences, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers59th pct.Of 17 peer CEOs
CEO pay, last three years
- $15,944,347FY2024
- $11,636,917FY2025
CEO total pay was $11,636,917 in fiscal 2025, down from $15,944,347 in fiscal 2024.
FY2025: salary $935,308 · bonus $716,040 · stock awards $9,215,500 · option awards $0
Executives and directors
Frank Lee · CEOJonathan Slonin · Chief Medical OfficerBrendan Teehan · CCOKristen Williams · ExecutiveShawn Cross · CFOAbraham Ceesay · Independent DirectorAlethia Young · Independent DirectorAndreas Wicki · Former director (through FY2025)Christopher Christie · Independent DirectorLaura Brege · Chair of the BoardMarcelo Bigal · Independent DirectorMark Froimson · Independent DirectorMark Kronenfeld · Independent DirectorMichael Yang · Independent DirectorPaul Hastings · Former director (through FY2025)Samit Hirawat · Independent DirectorThomas Wiggans · Independent Director
Frequently asked questions
Who was the highest-paid executive at Pacira BioSciences, Inc. in fiscal 2025?
As disclosed, Frank Lee (Chief Executive Officer and Director) was the highest-paid executive at Pacira BioSciences, Inc. in fiscal 2025, with total compensation of $11,636,917.
How does Pacira BioSciences, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Frank Lee's total compensation ranked at the 59th percentile of Pacira BioSciences, Inc.'s disclosed peer group.
What is Pacira BioSciences, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Pacira BioSciences, Inc.'s CEO-to-median employee pay ratio was 68:1.
How did shareholders vote on Pacira BioSciences, Inc.'s executive compensation?
As disclosed, 59.88% of shareholders supported Pacira BioSciences, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Pacira BioSciences, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Pacira BioSciences, Inc. reported total board compensation of $1,880,131 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Frank Lee | $935,308 | $716,040 | $9,215,500 | $0 | $738,810 | $0 | $31,259 | $11,636,917 |
| Chief Executive Officer and Director | ||||||||
| Brendan Teehan | 497,385 | 231,694 | 1,421,820 | 1,454,193 | 225,562 | 0 | 177,023 | 4,007,677 |
| Chief Commercial Officer | ||||||||
| Jonathan Slonin | 555,989 | 257,335 | 2,464,488 | 0 | 258,342 | 0 | 39,768 | 3,575,922 |
| Chief Medical Officer | ||||||||
| Kristen Williams | 545,080 | 262,560 | 2,085,336 | 0 | 253,328 | 0 | 34,172 | 3,180,476 |
| Chief Administrative Officer and Secretary | ||||||||
| Shawn Cross | 525,000 | 242,813 | 0 | 0 | 243,763 | 0 | 17,500 | 1,029,076 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Frank Lee | $11,636,917 | $15,944,347 | — | ↓ −4,307,430 |
| Brendan Teehan | 4,007,677 | — | — | — |
| Jonathan Slonin | 3,575,922 | 2,878,928 | 1,593,213 | ↑ +696,994 |
| Kristen Williams | 3,180,476 | 3,609,174 | 1,600,861 | ↓ −428,698 |
| Shawn Cross | 1,029,076 | 2,743,225 | — | ↓ −1,714,149 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation philosophy is performance-based and focuses on aligning the financial interests of our named executive officers with those of our stockholders. Our primary objective is to attract, retain, and motivate superior executive talent with the skills and experience to successfully execute our business strategy by providing competitive incentives that reward the achievement of performance goals designed to directly correlate to the enhancement of stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Kristen Williams | PSU | — | — | — | — | — | $2,085,336 |
| Brendan Teehan | OPTION | — | — | — | — | — | 1,454,193 |
| Frank Lee | PSU | — | — | — | — | — | 9,215,500 |
| Brendan Teehan | PSU | — | — | — | — | — | 1,421,820 |
| Shawn Cross | OPTION | 2024-11-04 | — | — | 200,000 | — | 1,347,228 |
| Shawn Cross | RSU | 2024-11-01 | — | — | 75,000 | — | 1,242,750 |
| Jonathan Slonin | PSU | — | — | — | — | — | 2,464,488 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Kristen Williams | $0 | $2,085,336 | $0 | 100.0% |
| Brendan Teehan | 0 | 1,421,820 | 1,454,193 | 49.4% |
| Frank Lee | 0 | 9,215,500 | 0 | 100.0% |
| Shawn Cross | 1,242,750 | 0 | 1,347,228 | 0.0% |
| Jonathan Slonin | 0 | 2,464,488 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kristen Williams | RSU | 2,475 | — | $64,053 |
| Jonathan Slonin | RSU | 2,475 | — | 64,053 |
| Kristen Williams | Option | 3,100 | 59.39 | — |
| Jonathan Slonin | Option | 3,100 | 59.39 | — |
| Jonathan Slonin | RSU | 3,750 | — | 97,050 |
| Kristen Williams | RSU | 5,474 | — | 141,667 |
| Jonathan Slonin | RSU | 5,474 | — | 141,667 |
| Jonathan Slonin | Option | 5,625 | 32.07 | — |
| Kristen Williams | Option | 10,310 | 38.74 | — |
| Jonathan Slonin | Option | 10,310 | 38.74 | — |
| Kristen Williams | RSU | 33,700 | — | 872,156 |
| Kristen Williams | RSU | 40,725 | — | 1,053,963 |
| Jonathan Slonin | RSU | 40,725 | — | 1,053,963 |
| Brendan Teehan | RSU | 54,000 | — | 1,397,520 |
| Shawn Cross | RSU | 56,250 | — | 1,455,750 |
| Frank Lee | RSU | 74,640 | — | 1,931,683 |
| Kristen Williams | RSU | 79,200 | — | 2,049,696 |
| Jonathan Slonin | RSU | 93,600 | — | 2,422,368 |
| Brendan Teehan | Option | 99,500 | 26.59 | — |
| Shawn Cross | Option | 150,000 | 16.45 | — |
| Frank Lee | RSU | 350,000 | — | 9,058,000 |
| Frank Lee | Option | 389,538 | 32.07 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Laura BregeIndependent · Board Chair · Nominating, Governance & Sustainability | $107,500 | $150,007 | $149,989 | $0 | $0 | $407,496 |
| Mark KronenfeldIndependent · Nominating, Governance & Sustainability (Chair) · People & Compensation · Science & Technology · Not standing for re-election | 89,000 | 150,007 | 149,989 | 0 | 0 | 388,996 |
| Alethia YoungIndependent · Audit (Chair) | 78,875 | 150,007 | 149,989 | 0 | 0 | 378,871 |
| Abraham CeesayIndependent · Audit · People & Compensation · Not standing for re-election | 75,875 | 150,007 | 149,989 | 0 | 0 | 375,871 |
| Michael YangIndependent · People & Compensation · Transaction | 74,000 | 150,007 | 149,989 | 0 | 0 | 373,996 |
| Mark FroimsonIndependent · Audit · Science & Technology | 74,000 | 150,007 | 149,989 | 0 | 0 | 373,996 |
| Marcelo BigalIndependent · People & Compensation · Science & Technology | 68,000 | 150,007 | 149,989 | 0 | 0 | 367,996 |
| Christopher ChristieIndependent · Nominating, Governance & Sustainability · Transaction | 58,325 | 150,007 | 149,989 | 0 | 0 | 358,321 |
| Paul HastingsIndependent · Departed during FY | 8,478 | 0 | 0 | 0 | 46,022 | 54,500 |
| Frank D. LeeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Samit HirawatIndependent · Science & Technology · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Thomas WiggansIndependent · Nominating, Governance & Sustainability · People & Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Andreas WickiNot independent · Departed during FY | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 24,000 / 18,000 |
| Stock ownership guideline | $150,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $634,053 |
| Equity awards (grant-date value) | $1,200,056 |
| All other compensation | $46,022 |
| Total cost of the board | $1,880,131 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Pacira BioSciences as a peer
Companies that benchmark against PCRX
21 companies name PCRX as a compensation peer
The list of companies that name PCRX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALKS Alkermes plcFOLD Amicus Therapeutics, Inc.BPMC Blueprint Medicines CorporationCORT Corcept Therapeutics, Inc.EXEL Exelixis, Inc.HALO Halozyme Therapeutics, Inc.IONS Ionis Pharmaceuticals, Inc.IRWD Ironwood Pharmaceuticals, Inc.PTCT PTC Therapeutics, Inc.TVTX Travere Therapeutics, Inc.ANIP ANI Pharmaceuticals, Inc.ORGO Organogenesis Holdings, Inc.DVAX Dynavax Technologies CorporationACAD ACADIA Pharmaceuticals, Inc.SUPN Supernus Pharmaceuticals, Inc.RARE Ultragenyx Pharmaceutical, Inc.CDNA CareDx, Inc.
Peer reciprocity
The companies Pacira BioSciences, Inc. names as compensation peers that name it back in their own disclosed peer groups.
PTC Therapeutics, Inc. (PTCT)74Travere Therapeutics, Inc. (TVTX)75Organogenesis Holdings, Inc. (ORGO)76Dynavax Technologies Corporation (DVAX)77ACADIA Pharmaceuticals, Inc. (ACAD)78Supernus Pharmaceuticals, Inc. (SUPN)79
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 5 | Corcept Therapeutics, Inc. | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 6 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 7 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 8 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 9 | Ultragenyx Pharmaceutical, Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 10 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 11 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 12 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 13 | Acadia Pharmaceuticals, Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 14 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 15 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 17 | Organogenesis Holdings, Inc. | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 18 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Acadia Pharmaceuticals, Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Corcept Therapeutics, Inc. | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Organogenesis Holdings, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical, Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 19,513,224 | 13,073,321 | 57,010 | 59.88% | Passed |
| 2025 | 2025-06-10 | 14,752,829 | 22,595,202 | 33,777 | 39.5% | Failed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 59.88%a |
| 2025 | 2025-06-10 | 39.5%b |
a. Approved under the standard stated in the filing — “ Abstentions have no effect--not counted as a vote.”.
b. Approved under the standard stated in the filing — “ Abstentions have no effect--not counted as a vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 68 : 1 |
|---|---|
| CEO total compensation | $15,944,347 |
| Median employee compensation | $233,124 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jonathan Slonin | Chief Medical Officer | 2026-06-03 | D | 4,728 | $22 | $105,529 | Common | Form 4 ↗ |
| Kristen Williams | Chief Administrative Officer | 2026-06-03 | D | 8,528 | 22 | 190,345 | Common | Form 4 ↗ |
| Lauren Riker | Senior Vice President, Finance | 2026-06-03 | D | 3,187 | 22 | 71,134 | Common | Form 4 ↗ |
| Kristen Williams | Chief Administrative Officer | 2026-06-04 | D | 10,259 | 22 | 228,468 | Common | Form 4 ↗ |
| Laura Brege | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Froimson | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Marcelo Bigal | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Michael Yang | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Alethia Young | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Christie | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samit Hirawat | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Marcelo Bigal | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas Wiggans | Director | 2026-06-10 | A | 32,675 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Yang | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Samit Hirawat | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Froimson | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Alethia Young | Director | 2026-06-10 | A | 10,891 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Brege | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Christie | Director | 2026-06-10 | A | 6,405 | 0 | 0 | Common | Form 4 ↗ |
| Lauren Riker | Senior Vice President, Finance | 2026-06-11 | D | 6,115 | 24 | 143,703 | Common | Form 4 ↗ |
| Jonathan Slonin | Chief Medical Officer | 2026-08-17 | D | 3,040 | 23 | 70,619 | Common | Form 4 ↗ |
| Lauren Riker | Senior Vice President, Finance | 2026-10-08 | D | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Riker | Senior Vice President, Finance | 2026-10-08 | D | 6,000 | 36 | 217,920 | Common | Form 4 ↗ |
| Lauren Riker | Senior Vice President, Finance | 2026-10-08 | A | 6,000 | 32 | 194,100 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (79 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Frank Lee. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE” · page 103. As printed: 11,636,917. View filing ↗
- Section 01, Brendan Teehan. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE”. As printed: 4,007,677. View filing ↗
- Section 01, Jonathan Slonin. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE”. As printed: 3,575,922. View filing ↗
- Section 01, Kristen Williams. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE”. As printed: 3,180,476. View filing ↗
- Section 01, Shawn Cross. DEF 14A, filed 2026-04-28. Section “SUMMARY COMPENSATION TABLE”. As printed: 1,029,076. View filing ↗
- Section 03, Kristen Williams PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brendan Teehan OPTION. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Frank Lee PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brendan Teehan PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Shawn Cross OPTION. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Shawn Cross RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Slonin PSU. DEF 14A, filed 2026-04-28. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-29. Section “CEO Pay Ratio”. As printed: 68 : 1. View filing ↗
- Section 08, Laura Brege. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 407,496. View filing ↗
- Section 08, Mark Kronenfeld. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 388,996. View filing ↗
- Section 08, Alethia Young. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 378,871. View filing ↗
- Section 08, Abraham Ceesay. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 375,871. View filing ↗
- Section 08, Michael Yang. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 373,996. View filing ↗
- Section 08, Mark Froimson. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 373,996. View filing ↗
- Section 08, Marcelo Bigal. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 367,996. View filing ↗
- Section 08, Christopher Christie. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 358,321. View filing ↗
- Section 08, Paul Hastings. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 54,500. View filing ↗
- Section 08, Frank D. Lee. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Samit Hirawat. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Thomas Wiggans. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Andreas Wicki. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jonathan Slonin 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Williams 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Riker 2026-06-03. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kristen Williams 2026-06-04. Form 4, filed 2026-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Brege 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Froimson 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcelo Bigal 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Yang 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alethia Young 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Christie 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Samit Hirawat 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcelo Bigal 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Wiggans 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Yang 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Samit Hirawat 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Froimson 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alethia Young 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laura Brege 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Christie 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Riker 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Slonin 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Riker 2026-10-08. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Riker 2026-10-08. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Riker 2026-10-08. Form 4, filed 2026-10-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 59.88% (votes for as printed: 19,513,224). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 39.5% (votes for as printed: 14,752,829). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 634,053 + equity 1,200,056 + all other 46,022 = 1,880,131, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- PTC Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics, Inc.'s own proxy. As printed: 15,303,551. View filing ↗
- Blueprint Medicines Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. View filing ↗
- Ionis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. View filing ↗
- Pacira BioSciences, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. View filing ↗
- Ultragenyx Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Ultragenyx Pharmaceutical, Inc.'s own proxy. As printed: 11,405,535. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Acadia Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals, Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Dynavax Technologies Corporation, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- CareDx, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Organogenesis Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Organogenesis Holdings, Inc.'s own proxy. As printed: 6,811,754. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Section 10a, PTC Therapeutics, Inc. reciprocity. DEF 14A. PTC Therapeutics, Inc. names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Travere Therapeutics, Inc. reciprocity. DEF 14A. Travere Therapeutics, Inc. names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Organogenesis Holdings, Inc. reciprocity. DEF 14A. Organogenesis Holdings, Inc. names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Dynavax Technologies Corporation reciprocity. DEF 14A. Dynavax Technologies Corporation names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ACADIA Pharmaceuticals, Inc. reciprocity. DEF 14A. ACADIA Pharmaceuticals, Inc. names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Supernus Pharmaceuticals, Inc. reciprocity. DEF 14A. Supernus Pharmaceuticals, Inc. names Pacira BioSciences, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗